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We describe two donor splice site mutations, affecting dystrophin exons 16 and
45 that led to Duchenne muscular dystrophy (DMD), through catastrophic
inactivation of the mRNA. These gene lesions unexpectedly resulted in the
retention of the downstream introns, thereby increasing the length of the dys-
trophin mRNA by 20.2 and 36 kb, respectively. Splice-switching antisense oligo-
mers targeted to exon 16 excised this in-frame exon and the following intron
from the patient dystrophin transcript very efficiently in vitro, thereby restoring
the reading frame and allowing synthesis of near-normal levels of a putatively
functional dystrophin isoform. In contrast, targeting splice-switching oligomers
to exon 45 in patient cells promoted only modest levels of an out-of-frame dys-
trophin transcript after transfection at high oligomer concentrations, whereas
dual targeting of exons 44 and 45 or 45 and 46 resulted in more efficient exon
skipping, with concomitant removal of intron 45. The splice site mutations
reported here appear highly amenable to antisense oligomer intervention. We
suggest that other splice site mutations may need to be evaluated for oligomer
interventions on a case-by-case basis.
Introduction
Duchenne muscular dystrophy (DMD), a fatal X-linked
muscle wasting disorder of childhood, is caused by muta-
tions in the dystrophin gene (DMD), most commonly
frame-shifting deletions of one or more exons (for review
Emery (2002)). The milder allelic condition, Becker mus-
cular dystrophy (BMD) is also caused by dystrophin
mutations, but these are typically in-frame deletions that
allow synthesis of internally truncated dystrophin isoforms
that retain partial function. Characterization of dystrophin
gene arrangements in mildly affected and asymptomatic
BMD individuals has revealed that deletion of substantial
domains of the DMD gene can yield dystrophin isoforms
of near-normal function. These observations led to the
concept of targeted exon removal around a DMD muta-
tion to reframe the dystrophin transcript, and the supposi-
tion that such a strategy could treat DMD.
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Splice-switching antisense oligomers were first used by
Dominski and Kole (1993) to modify splicing of the
b-globin transcript, and subsequently shown to induce
dystrophin exon 19 skipping and reading frame disruption
(Takeshima et al. 1995). Proof of concept that targeted
exon removal could restore dystrophin expression in vivo
was demonstrated in mdx mice (Mann et al. 2001), a dog
model of DMD (Yokota et al. 2009) and more recently in
DMD patients (van Deutekom et al. 2007; Kinali et al.
2009; Cirak et al. 2011; Goemans et al. 2011). Oligomer
design and clinical studies have focused on removing exons
that flank frame-shift deletions in the two dystrophin dele-
tion “hotspots,” however, numerous motifs control exon
selection and splicing, and mutations in any of these can
ablate gene expression and cause disease. Splice motif dis-
ruption prevents proper exon selection or results in the use
of cryptic splice sites that cause partial exon loss or intron
retention, and may generate multiple aberrant transcripts
(Fernandez-Cadenas et al. 2003), while deep intronic
mutations can activate pseudoexon inclusion in the mature
gene transcript. Although pseudoexon activation in the
dystrophin gene transcript is a rare event, this is the only
type of gene lesion for which targeted exon skipping would
lead to a normal full-length gene transcript. Gurvich and
colleagues reported two DMD cases caused by the inclu-
sion of pseudoexons, derived from introns 11 and 45, and
subsequent oligomer-induced skipping of the aberrant
exons (Gurvich et al. 2008).
Dystrophin splice site mutations have been relatively
neglected as targets in DMD therapeutic exon skipping
studies, despite reports that splice motif changes cause at
least 15% of all mutations in human inherited disease
(Krawczak et al. 1992) and in an early study, 7% of DMD/
BMD cases (Roberts et al. 1994). Correct exon selection
requires basic cis-acting elements important in exon recog-
nition, and canonical splice sites, embedded within the
context of noncanonical sequence that is conducive to
splice site recognition and binding of splicing factors
(Krawczak et al. 2007). Mutations to both canonical and
noncanonical sequences can weaken splice site recognition
and may result in exon skipping, but the consequences are
difficult to predict (De Conti et al. 2012). Donor splice site
definition is a key step in splice site recognition and muta-
tions affecting the exon–intron junction are reported to
result in exon skipping when the immediate vicinity is
devoid of alternative splice sites (Krawczak et al. 2007).
We report the use of splice-switching antisense oligo-
mers (AO) to by-pass two donor splice site mutations, one
involving exon 16 (DMD-16ss) and the other impacting
upon exon 45 processing (DMD-45ss). The inactivation of
these donor splice sites did not lead to exon skipping, as
may be expected (Krawczak et al. 2007) but instead caused
retention of the downstream introns. Despite this similar-
ity, one mutation responded to single exon skipping while
the other required dual exon skipping to overcome the dis-
ease-causing mutation and restore the open reading frame.
As we have found with other small dystrophin gene
lesions, it appears that the various dystrophin splice site
mutations will require personalized oligomer design and
exon skipping strategies on a case-by-case basis (Forrest
et al. 2010; Fragall et al. 2011; Adkin et al. 2012).
Materials and Methods
AO design and synthesis
2’-O-methyl (2OMe)-modified bases on a phosphorothio-
ate backbone were synthesized on an Expedite 8909 synthe-
sizer (Applied Biosystems, Melbourne, Australia), as
described previously (Adams et al. 2007). AO nomenclature
is based upon target exon number and oligomer annealing
coordinates as described by Mann et al. (2002), and oligo-
mers to the most amenable sites were prepared and supplied
by Sarepta Therapeutics (Bothell, WA) as phosphorodiami-
date morpholino oligomers conjugated to a cell penetrating
peptide (PPMO-k) ((RXR)4XB, where B = b-alanine;
R = l-arginine; X = 6-aminohexanoic acid) (Moulton et al.
2007, 2009; Jearawiriyapaisarn et al. 2008; Moulton and
Moulton 2010). Detailed design and optimization of oligo-
mer sequences targeting exon 16 for removal were reported
previously (Harding et al. 2006) and the exon 44, 45, and
46 oligomer sequences are shown in Table 1.
Cell culture and myogenic conversion
of fibroblasts
All normal and patient biopsy samples were collected with
informed consent and were deidentified. The use of
human tissue in this study has been approved by the Uni-
versity of Western Australia Human Ethics Committee
(approval number RA/4/1/2295). Fibroblasts and myo-
genic cells from normal and DMD patient muscle biopsies
were expanded and differentiated as described previously
(Adkin et al. 2012). Cells from the patient DMD-16ss, car-
rying the exon 16 donor splice site were obtained from a
muscle biopsy, while dermal fibroblasts were prepared
from a skin biopsy from the DMD patient (DMD-45ss)
with an exon 45 splice site mutation. Normal myogenic
cells were extracted from surplus muscle biopsy fragments
from patients undergoing elective procedures, with
informed consent. Fibroblasts were converted to myoblasts
through forced myogenesis (Lattanzi et al. 1998) by trans-
duction with a MyoD expressing adenovirus, Ad5.f50.A-
dApt.MyoD (The Native Antigen Company, Oxford,
U.K.), and then differentiated in low serum media. Briefly,
patient fibroblasts were cultured until 80% confluent,
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washed with phosphate buffered saline (PBS), detached
with 0.25% Trypsin (w/v) (Gibco, Life Technologies),
inactivated with medium containing 10% FCS, pelleted by
centrifugation at 600 g and then resuspended in DMEM
(Life Technologies) supplemented with 5% horse serum.
Ad5.f50.AdApt.MyoD was added at a multiplicity of infec-
tion of 200 and the cells were seeded at 30,000 cells per
well in 24 well plates that had been sequentially pretreated
for 1 h with 50 lg/mL poly D-lysine (Sigma, Melbourne,
Australia) and 100 lg/mL Matrigel (BD Biosciences,
North Ryde, Australia). Twenty-four hours later, the med-
ium was replaced. The cells were allowed to differentiate
for 96 h after forced myogenesis, before being transfected
with oligomers. In our experience, forced myogenesis of fi-
broblasts is adequate for RNA studies, but is not always
efficient enough to result in induced dystrophin levels that
are detectable by western blotting, and is very dependent
on the quality of the original cell preparation.
Transfection of myogenic cells, RNA
extraction, and nested RT-PCR
2OMe AOs were transfected as cationic lipoplexes with
Lipofectamine 2000 (1:1 w/w) (Life Technologies,
Melbourne, Australia) in Opti-MEM media (Gibco- Life
Technologies) as per the manufacturer’s instructions (Har-
ding et al. 2006). PPMO-k was transfected into the cells, at
concentrations indicated, and as described (Adkin et al.
2012). After incubation as specified, RNA was extracted
and RT-PCR undertaken using ~100 ng of total RNA as
template for primary amplification using Superscript III
One-step RT-PCR system with Platinum Taq (Life Tech-
nologies) to amplify across specified dystrophin exons.
After 30 cycles (myoblasts) and 35 cycles (MyoD converted
fibroblasts) a 1 lL aliquot was removed and subjected to
nested PCR for 30 cycles using AmpliTaq Gold (Applied
Biosystems, Melbourne, Australia). Details of PCR primers
(Geneworks, Adelaide, Australia) are shown in Table 2.
Gel analysis, imaging, and sequencing
Amplicons were fractionated on 2% agarose gels in TAE
buffer and relative exon skipping efficiency estimated by
densitometry of the full-length and oligomer-induced PCR
products on images captured by the Chemi-Smart 3000
system (Vilber Lourmat, Marne–la–Vallee, France) (Adams
et al. 2007). The identities of induced transcripts were
confirmed by direct DNA sequencing, undertaken by the
Australian Genome Research Facility (Perth, Australia).
Densitometric analysis used Bio1D software (Scientific
Software Group, Provo, UT).
Western analysis of dystrophin expression
DMD16-ss cells were transfected with oligomer sequences
targeting the exon 16 acceptor splice site, prepared as
Table 1. Splice-switching oligomer sequences targeting exons 16, 44, 45, and 46.
Coordinates Sequence (5’?3’) Patent number
H16A(12 + 19) CUAGAUCCGCUUUUAAAACCUGUUAAAACAA WO 2011/057350 A1
H44A(+65 + 92) UGAGAAACUGUUCAGCUUCUGUUAGCCA WO 2011/057350 A1
H45A(03 + 22) GCCCAAUGCCAUCCUGGAGUUCCUG WO 2011/057350 A1
H46A(+93 + 122) GUUGCUGCUCUUUUCCAGGUUCAAGUGGGA WO 2011/057350 A1
Table 2. PCR primer sequences and combinations used in this study.
PCR primer Sequence 5’?3’
Exon 1 Fo CTTTCCCCCTACAGGACTCAG
Exon 7 Ro CTTCAGGATCGAGTAGTTTCTC
Exon 1 Fi GGGAGGCAATTACCTTCGGAG
Exon 7 Ri CTGGCGATGTTGAATGCATGT
Exon 9 F CGATTCAAGAGCTARGCCTAC
Exon 18 R GGATCTCCAGAATCAGAAAC
Exon 12 F GCGAGTAATCCAGCTGTGAAG
Exon 17 R CCGTAGTTACTGTTTCCATTA
Exon 40 F CTCTAGAAATTTCTCATCAG
Exon 51 Ri GGTAAGTTCTGTCCAAGCCCGG
Exon 41 F AGAGCAAATTTGCTCAGTTTCG
Exon 47 R TTATCCACTGGAGATTTGTCTG
Exon 69 Fo GCAAAAGGCCATAAAATGCAC
Exon 75 Ro ACGGCAGTGGGGACAGGCCTTT
Exon 69 Fi CCCATGGTGGAATATTGCAC
Exon 75 Ri TGTTCGTGCTGCTGCTTTAGAC
Exon 13 F CACGCAACTGCTGCTTTGGAAG
Exon 15 F GATGCAGTGAACAAGATTCAC
Intron 16 R TCTCTGAGATAGTCTGTAGCATG
Intron 16 F GACTTTCGATGTTGAGATTACTTTCCC
Exon 21 R GGCCACAAAGCTTGCATCCAG
Exon 20 R CAGTTAAGTCTCTCACTTAGC
Intron 45 R 1 ATGCAAGAGCTTGGCAAAAGA
Intron 45 R 2 AAGCTTAAAAAGTCTGCTAAAATG
Intron 45 F TTGTGTCCCAGTTTGCATTAAC
Exon 47 R TTATCCACTGGAGATTTGTCTG
Exon 43 Fo GCAACGCCTGTGGAAAGGGTG
Exon 45 Ro CAGATTCAGGCTTCCCAATT
Exon 43 Fi CAGGAAGCTCTCTCCCAGC
Exon 45 Ri CCTGTAGAATACTGGCATCTGT
Outer primer combinations are shaded in gray, and inner primer com-
binations are indicated.
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PPMO-k (2 lmol/L) or a 2OMe AO cationic lipoplex
(400 nmol/L), and incubated for 7 days before harvesting
and western blot analysis (McClorey et al. 2006). Protein
extracts (~30 lg) from normal and DMD-16ss cells (oli-
gomer treated and untreated) were loaded onto denatur-
ing 3–10% gradient polyacrylamide gels. Electrophoresis
and western blotting were performed using NCL-DYS2
(Novocastra Laboratories, Newcastle-upon-Tyne, U.K.) in
a protocol derived from those of Cooper et al. (2003)
and Nicholson et al. (1989), and was described in detail
previously (Fletcher et al. 2006). Protein loading was
standardized according to myosin heavy chain expression,
assessed by densitometry on a Coomassie blue stained
gradient gel (Fletcher et al. 2006). Images were captured
on a Vilber Lourmat Chemi-Smart 3000 system using
Chemi-Capt software for image acquisition and Bio1D
software for image analysis.
Results
The exonic arrangement of the two regions of the dystro-
phin gene under investigation are shown in Figure 1,
indicating exon:intron sequences, intron length, and splice
site scores. Both mutations (c.1992 + 1 g>t and
c.6614 + 1 g>a) occurred at the invariant first “g” of in-
trons 16 and 45, respectively, ablating the canonical donor
splice sites. Splice site scores were determined using the
algorithm http://rulai.cshl.edu/new_alt_exon_db2/HTML/
score.html that predicts the maximum 5’ donor score as
12.6, with the average score of constitutive exons being
8.1. Hence, the normal exon 16 donor score of 8.0 is aver-
age (Fig. 1A), while the exon 16 donor splice site mutation
lowered the value to 2.7. The normal exon 45 donor
splice site (Fig. 1B) score of 7.1 was marginally below aver-
age, and the mutation reduced the value to 3.6. Dystro-
phin exon 16 is flanked by introns of 7.6 and 20.3 kb,
whereas exon 45 is flanked by introns of 248.4 and
36.1 kb.
Cells from the two patients, DMD-16ss and DMD-45ss,
were propagated and RNA extracted to assess the conse-
quences of these mutations on the mature dystrophin
gene transcript. RT-PCR across exons 12–17 (DMD-16ss)
produced either no signal or sporadic amplicons of vari-
ous lengths (Fig. 1C), while amplification across exons 41
to 47 (DMD-45ss) resulted in no product (data not
shown).
DMD-16ss studies
The failure to generate consistent RT-PCR products
across exons 12–17 from RNA extracted from untreated
DMD-16ss cells, suggested that the dystrophin transcript
was either absent, or present at extremely low levels.
However, amplification across exons 1–7 and 69–75 con-
firmed that the dystrophin mRNA was indeed present,




Exon 43           Intron 43         Exon 44              Intron 44 Exon 45////
   173b 70.4kb 148b                   248.4kb      176b
////Exon 45           Intron 45         Exon 46              Intron 46 Exon 47 
36.1kb 148b                   2.3kb         150b
Exon 15   Intron 15         Exon 16           Intron 16 Exon 17
   108b 7.6kb 180b                 20.3kb         176b
ACCGACAAGGgtaggtaacaca         ttttacctgcagGCGATTTGAC////GTATCTTAAGgtaagtctttga        ggtatcttacagGAACTCCAGG////
11 7











ACTGGCCgtatgtactttc        ttgttttaacagGTTTTAAAAG///////TACAGCACAGgttagtgatacc tacttctcacagATTTCACAGG
    7.4                                                .3                                            12.6                                             6.
                         7.1                                                13.2                                                9.0                                         5.1       
                       (-3.6
                3.1                                           8.5                                                8.0                                               8.9       
                                                                                                                   (-2.7)
Figure 1. Arrangement of dystrophin exons (A) 15–17, and (B) 43–47 indicating exon (upper case):intron (lower case italics) sequences, intron
length (shown in italics) and splice site scores, indicated by block arrows. Both mutations (c.1992 + 1 g>t and c.6614 + 1 g>a) occur at the
invariant first “g” of introns 16 and 45, respectively. Splice site scores were determined using the algorithm http://rulai.cshl.edu/
new_alt_exon_db2/HTML/score.html, and the scores resulting from the mutations are shown in parentheses. (C) RT-PCR across dystrophin exons
12–17 from RNA prepared from two independent untreated DMD-16ss myogenic cell cultures (ut). A 100 bp ladder was used as a size standard.
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tion conditions (Fig. 2A and B). RT-PCR was then car-
ried out using primer combinations to ascertain if intron
16 was retained within the mature mRNA. A forward pri-
mer directed to exon 15 and a reverse primer targeting
intron 16, as well as a forward primer annealing near the
end of intron 16 and a reverse primer targeting exon 20
were used. RT-PCR products were generated from the
patient RNA, corresponding to amplicons of the expected
length if intron 16 was retained, and the remainder of the
transcript had been correctly spliced (Fig. 2C and D). No
such signals were generated from RNA extracted from
normal human muscle and DNA sequencing of the exon
15F, intron16R product showed that dystrophin exon 15
was correctly spliced to exon 16, but the beginning of
intron 16 was retained in the transcript (data not shown).
Similarly, exons 17–20 were correctly spliced, but the end
of intron 16 was included in the patient transcript, lead-
ing us to conclude that the 20.3 kb intron 16 was
retained after splicing, expected to result in a full-length
muscle specific dystrophin transcript estimated to be in
excess of 34 kb (20.3 kb of intron retained within the
14 kb normal sized mRNA).
After transfection of cells from patient DMD-16ss with
a 2OMe-modified antisense oligomer targeting the exon
16 acceptor splice site, RNA was extracted and amplified
by nested RT-PCR. As shown in Figure 3, dystrophin
transcripts missing exon 16 were readily detected at all
but the lowest transfection concentrations. An amplicon
of near-normal length, detected in RNA extracted from
untreated cells (Fig. 3, ut lane) was generated sporadically
(Fig. 1C) and was previously identified as having arisen
from activation of a cryptic exon 16 donor splice site
(Mitrpant et al. 2009). The aberrant splice site is one base
upstream of the correct splice site, and has a calculated
donor splice site score of 4.7. The shorter amplicon,
apparent in the untreated samples, and cells transfected at
2.5 and 5 nmol/L was previously reported as having
arisen from spontaneous skipping of exons 14, 15, and 16
(Mitrpant et al. 2009).
Dystrophin expression studies were undertaken on
DMD-16ss myogenic cells, transfected with H16A
(12 + 19) prepared as 2OMe modified bases on a
phosphorothioate backbone (2OMeAO), and as a phosp-
horodiamidate morpholino oligomer coupled to a cell
penetrating peptide (PPMO-k). Near-normal levels of
dystrophin expression were detected in PPMO-k treated
patient cells, whereas those treated with the 2OMeAO
resulted in undetectable dystrophin expression under
these conditions (Fig. 4). This is consistent with our pre-
vious experience, where dystrophin could not be induced
to readily detectable levels in myogenic cells transfected
with 2OMeAOs (Fletcher et al. 2006; McClorey et al.
2006). The absence of dystrophin in the untreated patient
sample would indicate that the in-frame revertant fiber
transcripts missing exons 14–16 were present at levels too
low to generate detectable dystrophin.
DMD-45ss studies
RT-PCR across regions of the DMD-45ss dystrophin tran-
script, remote from the exon 45 gene lesion, indicated
that the mature dystrophin mRNA was present in the
DMD-45ss cells (Fig. 5A and B). The failure to reproduc-
ibly generate RT-PCR amplicons across exons 41–47, sug-
gested retention of intron 45, and this was confirmed by

























































Figure 2. RT-PCR across dystrophin exons 1–7 (A), and 69–75 (B) on
four separate RNA preparations from patient DMD-16ss. RT-PCR on
RNA prepared from DMD-16ss cells using a forward primer directed
to exon 15 and a reverse primer targeting intron 16 (C), and a
forward primer annealing near the end of intron 16 and a reverse
primer targeting exon 20 (D). RNA from normal human myogenic























Figure 3. RT-PCR of RNA extracted from patient DMD-16ss cells
transfected with a 2OMe modified antisense oligomer targeting exon
16, at concentrations indicated. The oligomer-induced amplicon
missing exon 16 is 536 bp, and the smaller product (326 bp) is a
revertant transcript missing exons 14–16 (reported previously Mitrpant
et al. (2009)). The larger amplicon (~700 bp) results from cryptic
splicing, and is present in all samples.
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RT-PCR using a forward primer targeting exon 43 with a
reverse primer annealing within intron 45, and a forward
primer annealing at the end of intron 45 with a reverse
primer targeting exon 47 (Fig. 5C and D). DNA sequenc-
ing confirmed the exon45:intron45:exon46 junctions (data
not shown) and, assuming that intron 45 is retained in its
entirety, would result in a 50 kb dystrophin transcript as
a consequence of the exon 45 donor splice site mutation.
The excision of exon 45 alone disrupts the dystrophin
reading frame, and hence it was necessary to excise either
exons 44 and 45 or exons 45 and 46 from the mature
mRNA to allow translation of a BMD-like dystrophin
isoform. Single and dual oligomer preparations targeting
these exons were transfected into normal myogenic cells,
and dose-dependent induction of exon skipping is shown
in Figure 6 A–E. Dual exon skipping of 44 and 45 and ex-
ons 45 and 46 appeared similarly efficient, with perhaps the
cocktail targeting exons 44 and 45 being marginally more
effective, as demonstrated by lower amounts of the full-
length dystrophin transcript amplicon (Fig. 6D and E).
Oligomers targeting exons 44, 45, and 46: H44A
(+65 + 97), H45A(03 + 22) and H46A (+93 + 122),
respectively, were transfected into DMD-45ss patient cells,
individually and in combinations. Single exon excision
did not generate detectable transcripts in the patient cells
(Fig. 6F–H), apart from application of H45A(03 + 22)
at the transfection concentrations of 50 to 100 nmol/L,
when amplicons of the expected size (missing exon 45)
were observed (Fig. 6G). The inability to amplify prod-
ucts from DMD-45ss RNA appears to be due to the
retention of intron 45 (36.1kb) in the patient dystrophin
mRNA, resulting in a transcript target size that would
preclude RT-PCR amplification.
Oligomer combinations targeting exons 44 and 45 and
exons 45 and 46 were transfected into the DMD-45ss
patient cells, and induced abundant transcript products
missing the targeted exon combinations. Exon 45 and 46
exclusion was efficiently induced at all concentrations
from 5 nmol/L and above, while exon 44 and 45 skipping
appeared less effective, reflected by the amount of
induced transcript and the presence of intermediate prod-
ucts in cells transfected with 2OMeAOs at 10 nmol/L or
less (Fig. 6I and J).
RT-PCR to detect dystrophin transcripts retaining
intron 45 confirmed that the failure to generate signals as
a result of single exon skipping was due to the retention
of intronic sequence. However, at transfection concentra-
tions of 25 nmol/L and above, the skipping of exons 44
and 45 completely suppressed intron 45 retention
(Fig. 7). Although transfection of patient cells with AOs
targeting exons 45 and 46 induced robust exon skipping,
intron 45 specific RT-PCR indicated the presence of tran-
scripts retaining intron 45 at all concentrations (data not
shown).
The forced myogenesis of dermal fibroblasts induces









































 Intron45F - Exon47R
Figure 5. RT-PCR across exons 1–7 (A), and 69–75 (B) of the normal
and DMD-45ss dystrophin transcripts. (C) RT-PCR using a forward
primer targeting exon 43 and a reverse primer annealing within intron
45 and (D) a forward primer annealing at the end of intron 45 with a





































Figure 4. Protein extracts from normal cells and oligomer-treated
and untreated DMD-16ss cells (~30 lg, standardized to myosin) were
analyzed by western blotting as described previously (McClorey et al.
2006). The 2OMe AO was transfected as a cationic lipoplex at
400 nmol/L and PPMO-k was added directly at 2 lmol/L, and the cells
were incubated for 7 days. Dystrophin expression was revealed by
NCL-DYS2 (Novocastra Laboratories) and chemiluminescent detection
with Western Breeze (Life Technologies). Myosin (lower band) is
indicated.
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and, when cell quality permits, protein analysis by western
blotting. However, in this case, the myogenic capacity of
the MyoD transduced DMD-45ss patient cells was not
adequate for dystrophin detection (data not shown).
Discussion
Antisense oligomer-mediated exon skipping to reframe
the dystrophin gene transcript is showing great promise
as a potential therapy to overcome DMD-causing muta-
tions. Dystrophin expression has been reported after sys-
temic administration of splice-switching oligomers, of
two different chemistries, in DMD patients (Cirak et al.
2011; Goemans et al. 2011). However, unlike gene or cell
replacement approaches for which one treatment should
be applicable to all DMD patients, regardless of the pri-
mary gene lesion, targeted exon skipping strategies must
be tailored to the mutation, and may have to be personal-
ized for some individuals. The first requirement is accu-
rate genetic diagnosis, with precise identification of the
gene lesion at the DNA, and preferably, the gene tran-
script level.
Mutation analysis at the DNA level can reliably iden-
tify gross genetic lesions and premature termination co-
dons as causes of genetic disease, however, several other
mechanisms can alter or disrupt gene expression, includ-
ing alterations that affect the fidelity of pre-mRNA splic-
ing (for review see Baralle et al. (2009)). The
consequences of small insertions, deletions, or point
mutations on the processing of the dystrophin gene
transcript can be difficult to predict, and therefore, the
clinical implications of such DNA changes are best
determined by transcript analysis, although this is com-
plicated by the necessity for RNA samples prepared from
the appropriate tissues.
Disruption of canonical splice sites would be expected





































































Figure 6. Normal (left panel) and DMD-45ss myogenic cells (right panel) were transfected with 2OMe phosphorothioate oligomers targeting
single exons 44 (A, F), 45 (B, G) or 46 (C, H) or the dual exon blocks, 44 and 45 (D, I), or 45 and 46 (E, J), at concentrations indicated. Nested
amplification used a forward primer in exon 41 and a reverse primer in exon 47 to generate a full-length transcript product of 1032 bases. The


















43 FO - Intron45R 2
Figure 7. RT-PCR from exon 43 to intron 45 to detect dystrophin
transcripts retaining intron 45, in the presence and absence of
oligomers targeting exons 44 and 45. The size of the amplicon
expected from retention of intron 45 is indicated (1159 bp).
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noncanonical bases, branch points, and splicing regulatory
elements are modulated by both cis and trans acting fac-
tors, and RNA secondary structure. An early estimate sug-
gested that 15% of all human point mutations result in
aberrant splicing (Krawczak et al. 1992), although this is
now recognized as an underestimation for some genes
(Baralle et al. 2009; Jensen et al. 2009). The importance
of aberrant splicing as a cause of human disease has lead
to advances in tools to predict the consequence of a par-
ticular nucleotide variation on gene expression (De Conti
et al. 2012), but uncertainties in modeling such complex
systems limits the accuracy of these predictions (Baralle
et al. 2009).
The most common consequence of mutations affecting
authentic splice sites is skipping of one or more exons,
followed by aberrant donor or acceptor splice activation
(Baralle and Baralle 2005; Buratti et al. 2007). Retention
of an entire intron is less commonly reported.
The majority of disease-causing point mutations that
affect splicing occur at the donor site (Krawczak et al.
2007). The results of a meta-analysis of disease-associated
splicing mutations are consistent with correct donor splice
site recognition being a key step in exon recognition, and
that 1.6% of pathogenic missense changes in human genes
are likely to affect mRNA splicing (Krawczak et al. 2007).
Splice site mutations in the DMD gene have been
reported to result either in DMD, BMD or intermediate
phenotypes in humans (Sironi et al. 2001; Adachi et al.
2003; Thi Tran et al. 2005; Takeshima et al. 2010; Magri
et al. 2011), and DMD-like disease in the naturally occur-
ring golden retriever (GRMD) canine model of DMD that
arises from a single base change affecting the dystrophin
exon 7 acceptor splice site (Sharp et al. 1992). The result is
omission of exon 7 from the mature dystrophin transcript,
and disruption of the reading frame that can be restored
by exclusion of exons 6 and 8, demonstrated in vitro
(McClorey et al. 2006) and in vivo (Yokota et al. 2009).
When first examining the dystrophin transcripts in cells
from the DMD patients, DMD-16ss and DMD-45ss, RT-
PCR across the gene lesions failed to yield reproducible
amplicons, a result that is inconsistent with skipping of
the respective exons. It was considered unlikely that non-
sense-mediated decay alone could account for what
appeared to be extremely low levels of transcript, as we
routinely detect dystrophin transcripts in many different
DMD patient cell and tissue samples, under equivalent
amplification conditions (Arechavala-Gomeza et al. 2007;
Forrest et al. 2010; Fragall et al. 2011; Adkin et al. 2012).
Hence, we hypothesized that a catastrophic disruption of
pre-mRNA processing may have ablated the dystrophin
transcript, downstream of the gene lesion. However,
amplification of the dystrophin mRNA upstream and
downstream of the defects indicated that the transcript
was indeed present in both cases, and the inability to gen-
erate products across the mutations was a limitation of
the RT-PCR. Undertaking RT-PCR with a forward primer
directed to exon 14 and reverse primers annealing within
intron 16 generated amplification products of the
expected size from DMD-16ss RNA, if intron 16 was
retained within the mature transcript. These amplicons
could not have arisen from DNA contamination as in-
trons 14 and 15, 110 bases and about 7.6 kb, respectively,
would preclude amplification under these conditions.
Similar experiments, using a forward primer annealing
toward the end of intron 16 and a reverse primer target-
ing exon 20 also generated a product of the anticipated
size if intron 16 was retained within the mature mRNA.
Shorter than expected amplicons were detected in RNA
extracted from untreated, and oligomer-treated DMD-
16ss cells, and have been reported previously (Mitrpant
et al. 2009). The smaller product detected most frequently
in this study was identified by DNA sequencing, and is
presumed to have arisen from endogenous skipping of
exons 14, 15, and 16, as this amplicon was also detected
in untreated DMD-16ss cells. Typical of the revertant
fiber transcripts reported to be present in at least 50% of
DMD patients (Sherratt et al. 1993; Winnard et al. 1993),
this particular transcript is in-frame but occurs at a very
low frequency, demonstrated by the sporadic detection at
the RNA level and absence of dystrophin on a western
blot.
Parallel RT-PCR studies confirmed that both ends of
intron 45 were present in the dystrophin mRNA expressed
in DMD-45ss cells, and primer walking indicated that at
least the first and last 1 kb of intron 45 was retained.
Northern blotting could confirm retention of the entire
intron 45 in the mature mRNA, but was not considered
necessary, as any internal cleavage should render the tran-
script susceptible to degradation by 5’–3’exonucleases,
such as Xrn2 (Davidson et al. 2012). Furthermore, the
inability to reproducibly generate amplicons across the
mutations studied here is consistent with retention of a
substantial portion of the introns. Consequently, the 14 kb
mature dystrophin mRNA would be increased in length
2.4 and 3.5 fold, by the exon 16 and 45 splice mutations,
respectively.
Transfection of the exon 16 targeting oligomer, H16A
(12 + 19), into DMD-16ss patient cells at concentra-
tions of 10 nmol/L or above, induced transcripts missing
exon and intron 16, were readily detected in a manner
that did not appear dose dependent. At a transfection
concentration of 5 nmol/L, the amplicon pattern was spo-
radic and similar to that observed in untreated cells, and
thus were assumed to indicate lack of rescue of the
transcript. Subsequent titration showed exon 16 skipping
could be induced in DMD-16ss patient cells after trans-
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fection at lower concentrations (1–10 nmol/L), but the
amplicon representing dystrophin transcripts missing
exon 16 only was sporadic (data not shown). This is con-
sistent with retention of intron 16 in the majority of the
transcripts, suggesting a possible threshold effect for
efficient splice switching for this mutation. Interestingly,
when we first reported exon skipping in normal human
myogenic cells with H16A(12 + 19) over the oligomer
transfection range 10–200 nmol/L (Harding et al. 2006), a
dose response was not apparent. Subsequent titration of
the oligomer in normal human myogenic cells showed a
clear dose response between 0.8 and 25 nmol/L (data not
shown), but this was not observed in the patient cells.
The inability to reliably induce exon 16 excision in the
DMD-16ss patient cells at low oligomer concentrations
could reflect the influence of the donor splice site muta-
tion on oligomer-induced modification of dystrophin
splicing in this patient. This was not unexpected, as we
have previously showed that small DMD mutations can
influence oligomer-mediated exon skipping outcomes
(Forrest et al. 2010; Fragall et al. 2011).
Mutations affecting dystrophin exon 16 are not com-
monly encountered and this exon would be considered to
be of low priority as a therapeutic target, except to the
patient and his family. Despite the rare, perhaps unique
nature of the mutation reported here, this patient could
be considered an excellent candidate for personalized
exon skipping. Not only can the target exon be excised at
high efficiency, at least in vitro, but more significantly,
the loss of exon 16 does not appear to compromise dys-
trophin function (Schwartz et al. 2007). By chance, sev-
eral members of a family were identified as missing this
exon, and these asymptomatic individuals did not show
elevated serum creatine kinase levels. The intent in apply-
ing exon skipping to the dystrophin transcript is to con-
vert a DMD pre-mRNA into a BMD-like isoform,
however, the loss of exon 16 from the mature dystrophin
gene transcript results in a dystrophin of normal function.
It is conceivable that induction of low levels of a “nor-
mal” dystrophin would confer substantial therapeutic
benefit, and therefore such patients may be better candi-
dates for clinical evaluation than those whose more com-
mon mutations only allow generation of a somewhat
compromised BMD-like dystrophin isoform.
Unlike exon 16, exon 45 is within the high priority dys-
trophin target region for induced exon skipping. Exclusion
of exon 45 is potentially applicable to an estimated 7–8% of
all DMD cases (van Deutekom and van Ommen 2003;
Aartsma-Rus et al. 2009). However, skipping of exon 45
alone will not be of any benefit to DMD-45ss, as dystrophin
transcripts missing exon 45 are out-of-frame, and dual
skipping of either exons 44 and 45 or 45 and 46 is required
for reading frame rescue.
Splice-switching oligomers previously designed and
optimized to excise exons 44, 45, and 46, and transfected
into normal myogenic cells either individually, or in com-
bination, induced robust, dose-dependent exon skipping.
The oligomers targeting exons 44 or 46 had no detectable
splice-switching effect in the DMD-45ss patient cells, and
our experience with DMD-16ss suggested that intron 45
was retained in the dystrophin mRNA, precluding ampli-
con generation. This was subsequently confirmed by nested
RT-PCR carried out from exon 43 to intron 45. The splice-
switching AO H45A(03 + 22) induced robust exon 45
skipping in normal cells at 50–100 nmol/L, with a decrease
in efficiency evident at lower concentrations. When the
oligomer was transfected into DMD-45ss patient cells,
there was a pronounced threshold effect, with oligomer
concentrations of 50 nmol/L and higher being necessary to
excise exon 45 and suppress intron 45 retention in the
DMD transcript in vitro.
Dual exon targeting efficiently excluded exons 44 and 45,
and exons 45 and 46 in DMD-45ss patient cells, with readily
detectable dystrophin amplicons of the expected size at
transfection concentrations of 5 nmol/L (2.5 nmol/L of
both oligomers) or higher. Exon 45 and 46 skipping
appeared to be the more effective strategy, as determined by
the relative amounts of the induced amplicon reflecting
dual exon skipping. Transfection of patient cells, with either
oligomer cocktail at 2.5 nmol/L did not induce any detect-
able product, suggesting retention of intron. Skipping of ex-
ons 44 and 45 appeared less effective, and specific RT-PCR
assays confirmed the presence of some transcripts retaining
intron 45. Surprisingly, the intron specific RT-PCR assays
indicated some transcripts retained intron 45 despite the
seemingly more efficient exon 45 and 46 skipping.
It is probable that the nature of these donor splice site
mutations, together with the size of the flanking introns
will impact upon oligomer-induced exon skipping. Over-
coming the exon 16 gene lesion was readily achieved by
skipping of this single exon, with flanking introns 15 and
16, a total expanse of 29.1 kb. In contrast, addressing the
exon 45 splice mutation necessitated removal of two
exons and the associated introns. Intron 44, the longest in
DMD and perhaps all genes, is over 248 kb in length.
Skipping exons 44 and 45 requires some 355 kb of pre-
mRNA to be excised, whereas the alternative strategy,
removing exons 45 and 46 excludes 286 kb from the
primary gene transcript. Two possibilities could account
for the variable dual exon skipping efficiencies. Not all
oligomers excise a targeted exon with equal efficiency,
exon 44 skipping in normal cells is less effective than
removal of exon 46, although this is further complicated
when using oligomer combinations. When assessed in
normal myogenic cells, the excision of exons 44 and 45
appeared more efficient than skipping of exon 45 and 46.
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Another consideration is the possibility of an upper limit
on the distance between exons that permit lariat forma-
tion and subsequent splicing.
In summary, we have described two DMD donor splice
site mutations that unexpectedly led to retention of the
entire downstream introns in the transcript, and some diffi-
culty in mRNA characterization, until RT-PCR primers
annealing to the introns were used. Despite this superficial
similarity, the DMD-16ss gene transcript responded to sin-
gle exon skipping, so that near-normal levels of dystrophin
were restored in vitro, as assessed by western blotting. In
contrast, the DMD-45ss dystrophin transcript was not
amenable to single exon skipping, whereas dual skipping of
exons 44 and 45 or 45 and 46 was efficiently induced, with
a clear threshold effect evident. We suggest that it is likely
that exon skipping strategies will need to be individualized
for many of the nondeletion DMD cases.
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